Altmetrics
Downloads
138
Views
121
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
28 June 2023
Posted:
29 June 2023
You are already at the latest version
Trial Name | Intervention | Phase | Study Design | Reference |
---|---|---|---|---|
INBUILD (NCT02999178) |
Nintedanib: 150 mg twice daily vs placebo | III | Randomized, double-blind, placebo-controlled, 663 patients with fibrosing lung disease | [97] |
INPULSIS I (NCT01335464) |
Nintedanib: 150 mg twice daily vs placebo |
III | Randomized, double-blind, placebo-controlled, 515 patients with IPF | [98] |
INPULSIS II (NCT01335477) |
Nintedanib: 150 mg twice daily vs placebo |
III | Randomized, double-blind, placebo-controlled, 551 patients with IPF | [98] |
PINCER (NCT04856111) |
Pirfenidone (600 mg daily, escalated by 600 mg daily every 3-7 days up to targeted dose of 2400 mg daily) vs. Nintedanib (150mg twice daily) | IV | Randomized, parallel-assignment, 48 patients with COVID-19 | [95] |
RELIEF (NCT03099187) |
Pirfenidone: 801mg three times daily vs. placebo |
IIb | Randomized, double-blind, placebo-controlled, 253 patients with unclassifiable progressive fibrosing ILD | [99] |
Fibrotic Disease | Drug/Therapy | Target | Target Expression Level | Phase | Study |
---|---|---|---|---|---|
Renal | RG-012 | miR-21 | Down-regulation | I/II | [112] |
Cardiac | Tanshinone IIA | miR-29b | Up-regulation | -- | [113] |
Cardiac | miR-101a-loaded MSC extracellular nanovesicles | miR-101a | Up-regulation | -- | [114] |
Lung | Remlarsen/MRG-201 | miR-29 | Down-regulation | II | [115] |
Lung | MRG-229 | miR-29 | Down-regulation | -- | [116] |
Liver | Miravirsen | miR-122 | Down-regulation | II | [117] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated